227 related articles for article (PubMed ID: 12437383)
21. A theoretical study of some new analogues of the anti-cancer drug camptothecin.
Jena NR; Mishra PC
J Mol Model; 2007 Jan; 13(1):267-74. PubMed ID: 17024403
[TBL] [Abstract][Full Text] [Related]
22. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
23. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
24. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
Kerrigan JE; Pilch DS
Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
[TBL] [Abstract][Full Text] [Related]
25. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
26. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
27. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
28. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
29. 14-azacamptothecin: a potent water-soluble topoisomerase I poison.
Cheng K; Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
J Am Chem Soc; 2005 Jan; 127(3):838-9. PubMed ID: 15656613
[TBL] [Abstract][Full Text] [Related]
30. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
31. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.
Wang X; Zhou X; Hecht SM
Biochemistry; 1999 Apr; 38(14):4374-81. PubMed ID: 10194356
[TBL] [Abstract][Full Text] [Related]
32. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
33. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
34. On the role of E-ring oxygen atoms in the binding of camptothecin to the topoisomerase I-DNA covalent binary complex.
Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
Bioorg Med Chem; 2005 Feb; 13(4):1381-6. PubMed ID: 15670945
[TBL] [Abstract][Full Text] [Related]
35. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
[TBL] [Abstract][Full Text] [Related]
36. Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons.
Rahier NJ; Eisenhauer BM; Gao R; Jones SH; Hecht SM
Org Lett; 2004 Feb; 6(3):321-4. PubMed ID: 14748583
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacology of camptothecin and its derivatives].
Rivory LP; Robert J
Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
[TBL] [Abstract][Full Text] [Related]
38. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 10,11-methylenedioxy-14-azacamptothecin.
Elban MA; Sun W; Eisenhauer BM; Gao R; Hecht SM
Org Lett; 2006 Aug; 8(16):3513-6. PubMed ID: 16869648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
